A short clinical guideline on new medications for blood glucose control for people with Type 2 diabetes has been published by NICE, the National Institute for Health and Clinical Excellence. This guideline is a partial update of the clinical guidelines for the management of Type 2 diabetes, published in 2008.
It covers the use of glitazones (pioglitazone and rosiglitazone), DPP-4 inhibitors (sitagliptin and vildagliptin), incretin mimetic (exenatide) and long acting insulin analogues (glargine and detemir). The guidance makes recommendations on the use of these newer agents, whilst also considering existing treatments for blood glucose control in Type 2 diabetes, identifying when and how these can all be used.
Although the guidance has the potential to support the increased choice of treatments available, Diabetes UK is disappointed that the guidelines have more restrictive recommendations surrounding the use of the newer medications.
Caroline Butler, care advisor at Diabetes UK said: "We believe treatment choice should be agreed between the person and their appropriately trained healthcare professional.
"Choice of treatment and its continuation should be based on the needs and goals of the individual whilst considering issues of clinical safety. People with diabetes should have access to objective information to help inform decision making based on the benefits and adverse effects."
Diabetes UK recognises that as newer medications are used more widely, further evidence will become available to help inform future prescribing practice.